1. Supplemental Figure 1.A. Frequency of CCND1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

2. Supplemental Figure 1.B. Frequency of CCND2 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

3. Supplemental Figure 1.C. Frequency of CCND3 aberration by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

4. Supplemental Figure 1.D. Frequency of CDK4 amplification by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

5. Supplemental Figure 1.E. Frequency of CDK6 amplification by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

6. Supplemental Figure 1.F. Frequency of CDKN2A/B aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

7. Supplemental Figure 1.G. Frequency of CCNE1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

8. Supplemental Figure 1.H. Frequency of RB1 aberrations by tumor type. Included primary cancer diagnosis with N ≥ 20. See Supplemental Table 1 for complete list of cancer diagnosis with N < 20. Frequencies of aberration were calculated as a percentage of the number of tumors of that type.

9. Supplemental Figure 2.A. Comparison of CCND1 aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCND1 aberrations from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

10. Supplemental Figure 2.B. Comparison of CCND2 aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCND2 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

11. Supplemental Figure 2.C. Comparison of CCND3 aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCND3 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

12. Supplemental Figure 2.D. Comparison of CDK4 aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CDK4 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

13. Supplemental Figure 2.E. Comparison of CDK6 aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CDK6 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

14. Supplemental Figure 2.F. Comparison of CDKN2A/B aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CDKN2A/B aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

15. Supplemental Figure 2.G. Comparison of CCNE1 aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with CCNE1 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.

16. Supplemental Figure 2.H. Comparison of RB1 aberrations between current report and cBioPortal data (http://cbioportal.org).http://cbioportal.org * * * * cBioPortal data available for mutation only. Included 10 most common cancer diagnoses associated with RB1 aberration from current report and when cBioPortal data were available for corresponding diagnosis. Data from cBioPortal are highlighted in diagonal patterns.